These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23588081)

  • 41. KIT Oncogenic Mutations: Biologic Insights, Therapeutic Advances, and Future Directions.
    Fletcher JA
    Cancer Res; 2016 Nov; 76(21):6140-6142. PubMed ID: 27803101
    [No Abstract]   [Full Text] [Related]  

  • 42. Radiofrequency ablation is a valuable therapeutic option in the treatment of liver metastases from gastrointestinal stromal tumors.
    Sun QK; Wang W; Jia WD
    Cardiovasc Intervent Radiol; 2014 Apr; 37(2):552-3. PubMed ID: 23917966
    [No Abstract]   [Full Text] [Related]  

  • 43. Drug binding and resistance mechanism of KIT tyrosine kinase revealed by hydrogen/deuterium exchange FTICR mass spectrometry.
    Zhang HM; Yu X; Greig MJ; Gajiwala KS; Wu JC; Diehl W; Lunney EA; Emmett MR; Marshall AG
    Protein Sci; 2010 Apr; 19(4):703-15. PubMed ID: 20095048
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT missence mutations.
    Malik L; Hemmings C; Beshay V; Fox S; Yip D
    Pathology; 2013 Oct; 45(6):604-6. PubMed ID: 24018806
    [No Abstract]   [Full Text] [Related]  

  • 45. Promiscuity and the conformational rearrangement of drug-like molecules: insight from the protein data bank.
    He MW; Lee PS; Sweeney ZK
    ChemMedChem; 2015 Feb; 10(2):238-44. PubMed ID: 25491400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KIT gene deletion in a gastrointestinal stromal tumor of the small intestine.
    Uccini S; Duranti E; Al-Jadiry MF; Al-Hadad SA; Testi AM; Dominici C
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):e25. PubMed ID: 22659889
    [No Abstract]   [Full Text] [Related]  

  • 47. The C-kit receptor-mediated signal transduction and tumor-related diseases.
    Liang J; Wu YL; Chen BJ; Zhang W; Tanaka Y; Sugiyama H
    Int J Biol Sci; 2013; 9(5):435-43. PubMed ID: 23678293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A case of gastrointestinal stromal tumor with internal tandem duplication in the 3'-terminal of the KIT juxtamembrane domain.
    Kato H; Nakamura M; Orito E; Ueda R; Tsuzuki T; Mizokami M
    Dig Dis Sci; 2005 Jan; 50(1):70-7. PubMed ID: 15712640
    [No Abstract]   [Full Text] [Related]  

  • 49. The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.
    Reshetnyak AV; Opatowsky Y; Boggon TJ; Folta-Stogniew E; Tome F; Lax I; Schlessinger J
    Mol Cell; 2015 Jan; 57(1):191-201. PubMed ID: 25544564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gastrointestinal Stromal Tumors With De Novo Anaplastic Dedifferentiation: Considerations on a Little-Known Neoplastic Metamorphosis.
    Virgilio E; Mercantini P; Tarantino G; Socciarelli F; Pilozzi E; Uccini S; Caterino S; Ziparo V
    Int J Surg Pathol; 2014 Jun; 22(4):385. PubMed ID: 24487042
    [No Abstract]   [Full Text] [Related]  

  • 51. Space-related pharma-motifs for fast search of protein binding motifs and polypharmacological targets.
    Chiu YY; Lin CY; Lin CT; Hsu KC; Chang LZ; Yang JM
    BMC Genomics; 2012; 13 Suppl 7(Suppl 7):S21. PubMed ID: 23281852
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Correlation between the expression defects of succinate dehydrogenase subunit protein and its gene mutation in succinate dehydrogenase-deficient gastrointestinal stromal tumors].
    Zhang YJ; Cheng YH; Zhang ZF; Guo LX; Li LH
    Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):661-663. PubMed ID: 34078058
    [No Abstract]   [Full Text] [Related]  

  • 53. Cell line models identify different sensitivity of mutant forms of c-KIT to kinase inhibitory drugs and predict the response of patients to therapy.
    Ashman LK
    Mol Cancer Ther; 2011 Nov; 10(11):2032-3. PubMed ID: 22072814
    [No Abstract]   [Full Text] [Related]  

  • 54. Evaluation of chemically modified carrier proteins for developing monoclonal antibodies against a clinically relevant mutation of cKIT.
    Jara-Acevedo R; Gonzalez-Gonzalez M; Jara-Acevedo M; Claros J; Conde A; López-Perez R; Orfao A; Fuentes M
    J Immunol Methods; 2012 Oct; 384(1-2):171-6. PubMed ID: 22835433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel KIT gene missense mutation in a Japanese family with piebaldism.
    Nomura K; Hatayama I; Narita T; Kaneko T; Shiraishi M
    J Invest Dermatol; 1998 Aug; 111(2):337-8. PubMed ID: 9699740
    [No Abstract]   [Full Text] [Related]  

  • 56. Spotted Weimaraner dog due to de novo KIT mutation.
    Gerding WM; Akkad DA; Epplen JT
    Anim Genet; 2013 Aug; 44(5):605-6. PubMed ID: 23659249
    [No Abstract]   [Full Text] [Related]  

  • 57. The evolution of a revolutionary class: extending benefits of tyrosine kinase inhibitors--introduction.
    Blay JY; Demetri GD
    Semin Oncol; 2011 Apr; 38 Suppl 1():S1-2. PubMed ID: 21419930
    [No Abstract]   [Full Text] [Related]  

  • 58. Molecular dynamics simulations in drug design.
    Kerrigan JE
    Methods Mol Biol; 2013; 993():95-113. PubMed ID: 23568466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour.
    Alyuruk H; Calibasi G; Cavas L; Baskin Y; Oztop I; Ellidokuz H; Yilmaz U
    Eur J Cancer; 2013 Jul; 49(10):2449-52. PubMed ID: 23588081
    [No Abstract]   [Full Text] [Related]  

  • 60. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
    Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.